Dr. Marina Kremyanskaya
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Myelofibrosis
Studies Uterine Tumors
4 reported clinical trials
5 drugs studied
Area of expertise
1Myelofibrosis
Stage I
Stage II
CALR exon 9 positive
2Uterine Tumors
Stage I
Stage II
CALR exon 9 positive
Affiliated Hospitals
Clinical Trials Marina Kremyanskaya is currently running
Reparixin
for Myelofibrosis
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
Recruiting1 award Phase 2
Peptide-based Vaccine
for Myeloproliferative Disorders
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Recruiting1 award Phase 1
More about Marina Kremyanskaya
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Marina Kremyanskaya has experience with
- Mutant CALR-peptide Based Vaccine
- Luspatercept
- Placebo
- Pelabresib (CPI-0610)
- Reparixin
Breakdown of trials Marina Kremyanskaya has run
Uterine Tumors
Myeloproliferative Disorders
Thrombocythemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marina Kremyanskaya specialize in?
Marina Kremyanskaya focuses on Myelofibrosis and Uterine Tumors. In particular, much of their work with Myelofibrosis has involved Stage I patients, or patients who are Stage II.
Is Marina Kremyanskaya currently recruiting for clinical trials?
Yes, Marina Kremyanskaya is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Marina Kremyanskaya has studied deeply?
Yes, Marina Kremyanskaya has studied treatments such as Mutant CALR-peptide Based Vaccine, Luspatercept, Placebo.
What is the best way to schedule an appointment with Marina Kremyanskaya?
Apply for one of the trials that Marina Kremyanskaya is conducting.
What is the office address of Marina Kremyanskaya?
The office of Marina Kremyanskaya is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.